Li Weizhi, Liu Mengying, Guan Sheng, Ding Pengxu, Yuan Jia, Zhao Yan, Li Peijie, Ma Fuquan, Xue Hui
Department of Gastroenterology, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, Shaanxi, 710061, China.
Department of Vascular Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
CVIR Endovasc. 2024 Oct 18;7(1):76. doi: 10.1186/s42155-024-00489-9.
To compare clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) created with the single covered-uncovered stent (Viatorr TIPS Endoprosthesis) versus covered stent (Fluency) versus a combination of covered and uncovered stent.
From May 2016 and July 2019, a total of 180 liver cirrhosis patients with recurrent variceal bleeding underwent TIPS creation with single covered-uncovered stent (n = 63) or covered stent (n = 41) or a covered and uncovered stent combination (n = 76). Shunt dysfunction, rebleeding, overt hepatic encephalopathy and mortality was estimated using the Kaplan-Meier method and compared with the log-rank test.
The difference of baseline characteristics among these three groups were not significant. The included patients had a median age of 51 years (IQR 43-61), and 101 (56.1%) were men. The 1-year and 2-year shunt dysfunction rates were 1.6% and 3.2% in the single covered-uncovered stent group, 7.3% and 7.3% in the covered stent group and 5.3% and 6.6% in the combination group, respectively. There was no significant difference among groups [Hazard Ratio (HR) (95%CI): 1 vs 2.29 (0.38 - 13.72) vs 2.10 (0.41 - 10.83); P = 0.913]. No significant differences in the incidence of all-cause rebleeding were observed between the groups at 1 year (Viatorr vs Fluency vs combination: 11.1% vs 17.1% vs 10.5%) as well as 2 years (15.9% vs 17.1% vs 11.8%), with the HR (95%CI) being 1 vs 1.27 (0.5-3.21) vs 0.74 (0.30-1.82); P = 0.475). The 1-year and 2-year incidence of overt hepatic encephalopathy were 30.2% and 30.2% in the single covered-uncovered stent group, 22.0% and 22.0% in the covered stent group and 25.0% and 25.0% in the combination group, respectively. However, there was no significant difference among these three groups (P = 0.402). In addition, there was no significant difference in the 1-year and 2-year mortality (6.3% and 7.9% vs. 4.9% and 9.8% vs. 6.6% and 9.2%, P = 0.606).
No significant difference was observed among different stent groups. Fluency covered stent and the generic bare stent/Fluency covered stent was not an unreasonable alternative to the Viatorr stent for TIPS creation.
比较使用单枚覆膜-未覆膜支架(Viatorr TIPS内支架)、覆膜支架(Fluency)以及覆膜与未覆膜支架组合创建经颈静脉肝内门体分流术(TIPS)的临床结果。
2016年5月至2019年7月,共有180例肝硬化并复发性静脉曲张出血患者接受了TIPS创建,其中使用单枚覆膜-未覆膜支架(n = 63)、覆膜支架(n = 41)或覆膜与未覆膜支架组合(n = 76)。使用Kaplan-Meier方法评估分流功能障碍、再出血、显性肝性脑病和死亡率,并通过对数秩检验进行比较。
这三组患者的基线特征差异无统计学意义。纳入患者的中位年龄为51岁(四分位间距43 - 61岁),男性101例(56.1%)。单枚覆膜-未覆膜支架组1年和2年的分流功能障碍发生率分别为1.6%和3.2%,覆膜支架组分别为7.3%和7.3%,组合组分别为5.3%和6.6%。组间差异无统计学意义[风险比(HR)(95%可信区间):1对比2.29(0.38 - 13.72)对比2.10(0.41 - 10.83);P = 0.913]。1年时(Viatorr对比Fluency对比组合:11.1%对比17.1%对比10.5%)以及2年时(15.9%对比17.1%对比11.8%),各组间全因再出血发生率差异无统计学意义,HR(95%可信区间)为1对比1.27(0.5 - 3.21)对比0.74(0.30 - 1.82);P = 0.475)。单枚覆膜-未覆膜支架组1年和2年显性肝性脑病发生率分别为30.2%和30.2%,覆膜支架组分别为22.0%和22.0%,组合组分别为25.0%和25.0%。然而,这三组间差异无统计学意义(P = 0.402)。此外,1年和2年死亡率差异无统计学意义(6.3%和7.9%对比4.9%和9.8%对比6.6%和9.2%,P = 0.606)。
不同支架组间未观察到显著差异。对于创建TIPS,Fluency覆膜支架以及普通裸支架/Fluency覆膜支架组合是Viatorr支架的合理替代选择。